Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer - Test2 - elhamkhani - TriplyDB

Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer

Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer

http://www.wikidata.org/entity/Q24542039

about

sameAs

Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status Prostate cancer relevant antigens and enzymes for targeted drug delivery A high-resolution structure of ligand-free human glutamate carboxypeptidase II Structural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate Analogs X-ray structure of ILL2, an auxin-conjugate amidohydrolase fromArabidopsis thaliana Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studies Crystal structure of bacteriophage ϕNIT1 zinc peptidase PghP that hydrolyzes γ-glutamyl linkage of bacterial poly-γ-glutamate Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities Molecular identification of β-citrylglutamate hydrolase as glutamate carboxypeptidase 3 The Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 Deficiency The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen.N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2).Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.GCPII imaging and cancer.Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).Extracellular proteases as targets for drug development Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.Structural and biochemical characterization of a novel aminopeptidase from human intestine.Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration.Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen Substrate specificity of prostate-specific membrane antigen.Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.Nanoformulation of natural products for prevention and therapy of prostate cancer.DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.Targeting the prostate-specific membrane antigen for prostate cancer therapy.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer PET imaging in prostate cancer: focus on prostate-specific membrane antigen Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

P2860

Q24298320-60EDDA98-B2C6-4165-96E8-2F25AD62016F Q26774920-4E99C80D-6F84-41D8-B71F-92D37C71E1D9 Q27013843-88F2B941-086A-4112-8ACE-24FFDDA9DD45 Q27643940-13F3F77C-F845-4E45-BB3D-9DC6DC4A6808 Q27649737-01E78960-1B69-4517-B316-4F1C1D3FB2BD Q27650791-335D39FC-D377-4CA5-ADE8-4CDFAAE6E15B Q27653047-A5176DAA-8CA1-4181-8AB6-1A5BB85F817A Q27658096-768EB8B9-8BFD-4686-809A-2BE6AD0E4B99 Q27675746-0C75F9EC-AE22-4921-87D3-1F49BEC083E6 Q27704910-3A1C02B7-5AC6-4101-A107-F9B1E80F387E Q28508757-73C930B6-1880-4C22-AC59-CA6EAAF2D835 Q28830661-B8527404-CCF2-42BE-98F8-9D5D08179946 Q33299095-B9EFF32E-51AF-48C8-97F9-C5811CBC2F4E Q33789515-2626B9A5-A85D-48A0-BC61-0565255565B0 Q33820631-E93C0896-AE6A-465E-9898-E85914CDB6A5 Q33827632-1D8F0590-48A1-4916-A2BC-AEBCF355241E Q34038524-F5F77E3E-9D4A-418C-A917-3B44F47F822B Q34284930-C6CD9971-BD4A-4A48-9F30-60C4C3A99A46 Q34344595-480A752B-1CE4-44CD-B661-4FBF527B4939 Q34345914-9C126919-D66B-4779-B04C-9FE87557BA75 Q34918072-F1AD1180-35B3-4366-8B1D-E1989EE30317 Q35116202-B075EDAB-B6C3-48C8-9F48-6203C95B8E12 Q35282416-18E181EA-A660-4D8F-9255-014524A4A0DD Q35446801-93A6FCC1-C8A0-402E-A719-85D8E47EF270 Q35560986-9BA6568F-40D1-4944-8B35-A39677AE1DFF Q35685315-8887B851-6ABE-4850-94C6-EED5B488754A Q35926706-464B8B92-3A82-4B71-A4A6-416FCC1F6229 Q36054736-E59822A9-61CF-480F-AD3A-BFF4159B871C Q36160805-26A4D4FD-A865-4DDA-9A79-CEBD76309BCB Q36460130-A8565B80-D1FE-4D64-ACF3-C03DDA8F8B02 Q36477594-D2D8A07F-A50B-46FC-A270-1F9FB6E22261 Q36478758-30E0699B-09A2-4AFB-AB42-3D45D073B3DA Q36867784-97D20709-D3CF-4A93-BBFF-497DBBE8A17A Q37354387-34018C4D-BDEB-4D06-B023-B17BFAF71BC9 Q37473193-B8411386-2191-4A3B-8791-5C8F27F4BDE7 Q37649509-56BEFC64-749D-4858-92DD-B9C8DDAE2F80 Q37773273-172EC4E0-5B57-434E-8417-7148A5A98D3E Q37972920-F2CF279D-6488-49BA-8262-5EF90B3099E7 Q38099369-9B625787-5267-4A03-9C39-A7CD632CB3B4 Q38212231-5A46331E-6486-4E38-A5DB-0E87A2BEF241

P2860

Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer

http://www.wikidata.org/entity/Q24542039

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Structure of glutamate carboxy ...... nal damage and prostate cancer

@ast

Structure of glutamate carboxy ...... nal damage and prostate cancer

@en

Structure of glutamate carboxy ...... nal damage and prostate cancer

@nl

type

label

Structure of glutamate carboxy ...... nal damage and prostate cancer

@ast

Structure of glutamate carboxy ...... nal damage and prostate cancer

@en

Structure of glutamate carboxy ...... nal damage and prostate cancer

@nl

prefLabel

Structure of glutamate carboxy ...... nal damage and prostate cancer

@ast

Structure of glutamate carboxy ...... nal damage and prostate cancer

@en

Structure of glutamate carboxy ...... nal damage and prostate cancer

@nl

P1433

Q24542039-92765085-54C3-474F-989B-D1D3475EC061

P1476

Q24542039-B27C2DD1-D6C9-4EC8-8D4C-A4B3CF0FC487

P2093

Q24542039-2629FF68-181F-4DCA-8D11-D22B4CEB2D97

Q24542039-695489F4-4453-4B3E-815F-5AED8B9F3879

Q24542039-721BDEC3-9DCB-4CCA-95BD-14E3EB807EB1

Q24542039-8C32B801-5C25-42E0-90E0-0BC32A6CF0BD

Q24542039-BD34388B-9F12-4A06-BF3F-EAB7A75D1F41

P2860

Q24542039-033D9AA0-F8FC-4B05-91A4-31B185575605

Q24542039-038BD0F6-3359-4DAE-B98B-C9F37E03C87B

Q24542039-131A13A6-8352-4DCC-B1CA-CBC0BBEDCDFD

Q24542039-1C11A5FE-1C63-43B5-9DFC-A8540446B05A

Q24542039-22449359-0A8A-4874-8AE0-2A95DCFC1D7C

Q24542039-28BF8630-1AC0-484D-AD62-47A3C25F277E

Q24542039-2AF4060F-7813-47F8-B828-5CD3A3B287EA

Q24542039-346581F1-4BA7-4903-BA74-75D8B9353F23

Q24542039-38E6716E-B644-46D2-BF8A-0EEADFF2C7CF

Q24542039-3A1C277C-AB6E-4649-8B15-2487AF6DF0A4

P304

Q24542039-EED37DB5-974E-45E7-838C-5ECAEF77A049

P31

Q24542039-913DE563-59DC-406D-A16B-02AB154B3784

P356

Q24542039-558A7606-3C59-40A4-80D9-F9A6F6EFF79F

P407

Q24542039-AAB3B7A4-4805-47BC-AD2D-9FEB7D90451E

P433

Q24542039-83A2FD7C-57C4-4635-90FE-22BE978FDBD6

P478

Q24542039-08FED7D0-E86D-4889-94A3-420A1C8A6CCA

P50

Q24542039-24023A69-45ED-46D1-AE20-14A2E885D214

Q24542039-521D05BA-3B5D-46DA-A6EB-98261258A533

Q24542039-52875301-8AB3-4815-B8DA-C57FE2783AFC

Q24542039-EA9DFA27-F798-43E3-AF67-A7ECBCF25593

P577

Q24542039-C2E53808-0676-4FB0-AB37-0BD236C5930E

P5875

Q24542039-533A78E8-9FCA-4AC8-9B06-77311519B772

P698

Q24542039-0936257C-77F7-4365-9D5C-8787A7C1FC1D

P932

Q24542039-29685320-6A1B-4FE8-9BF7-EF952D9F5A4E

P356

SJ.EMBOJ.7600969

P1433

The EMBO Journal

P1476

Structure of glutamate carboxy ...... nal damage and prostate cancer

@en

P2093

Barbara S Slusher

http://www.w3.org/2001/XMLSchema#string

Cyril Barinka

http://www.w3.org/2001/XMLSchema#string

Jeroen R Mesters

http://www.w3.org/2001/XMLSchema#string

Takashi Tsukamoto

http://www.w3.org/2001/XMLSchema#string

Weixing Li

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor

Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen

The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold.

Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins

Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity

Crystal structure of the ectodomain of human transferrin receptor

The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism

Crystal structure of Aeromonas proteolytica aminopeptidase: a prototypical member of the co-catalytic zinc enzyme family

Streptomyces griseus aminopeptidase: X-ray crystallographic structure at 1.75 A resolution

Refinement of macromolecular structures by the maximum-likelihood method

P304

1375-1384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.EMBOJ.7600969

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Rolf Hilgenfeld

P577

2006-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7306301

http://www.w3.org/2001/XMLSchema#string

P698

16467855

http://www.w3.org/2001/XMLSchema#string

P932

1422165

http://www.w3.org/2001/XMLSchema#string